Status:

UNKNOWN

Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

Lead Sponsor:

Innolife Co., Ltd.

Conditions:

Heart Failure

Reduced Ejection Fraction

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to eva...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of HF requiring chronic treatment of loop diuretics
  • Left Ventricular Ejection Fraction (LVEF) ≤ 40% at screening by echocardiography
  • N-Terminal-prohormone of Brain Natriuretic Peptide (NT-proBNP) ≥400 pg/mL at screening for patients without atrial fibrillation or atrial flutter, or, NT-proBNP ≥ 1,200 pg/mL at screening for patients with atrial fibrillation or atrial flutter
  • Treated for Heart Failure with stable, optimal pharmacological therapy
  • Acceptable screening echocardiographic image quality

Exclusion

  • Female patients of childbearing potential
  • Patients with a New York Heart Association (NYHA) Class I or IV
  • Heart failure that is clearly caused by toxin / drug such as Adriamycin
  • Significant medical conditions or recent history suggesting the patient's study participation will potentially pose a major risk to patient's safety and well-being
  • Need for routine scheduled outpatient IV infusions for Heart Failure or scheduled ultrafiltration
  • History of rhabdomyolysis or history of autoimmune diseases
  • Severe renal disease
  • Hepatic disease
  • Pulmonary disease limiting exercise capacity
  • Atrial fibrillation with rapid ventricular response
  • Life expectancy of less than 6 months
  • Type 1 diabetes mellitus or Type 2 diabetes mellitus with very poor glycemic control
  • Patients with anemia

Key Trial Info

Start Date :

January 20 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2023

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT03875183

Start Date

January 20 2020

End Date

January 1 2023

Last Update

March 31 2022

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

UCLA School of Medicine

Torrance, California, United States, 90502

2

Innovative Research of West Florida, Inc.

Clearwater, Florida, United States, 33756

3

Universal Axon Clinical Research

Doral, Florida, United States, 33166

4

Grady Clinical Research Center

Atlanta, Georgia, United States, 30303